🔗 Permalink

Inventor profile of:

Mahmoud Ameri

City:

Fremont, California

Country:

United States

Published Applications:

Last publication date:

2024-06-06

Top Assignees for applications by Mahmoud Ameri

The entities that hold a legal rights for patent applications filed by inventor Ameri Mahmoud:

ALZA Corporation 9 Mountain View, CA United States
ALZA CORPORATION 7 Vacaville, CA United States
Emergex USA Corporation 5 Doylestown, PA United States
Zosano Pharma Corporation 2 Fremont, CA United States
ZP OPCO, INC. 2 Fremont, CA United States

Recent patent applications by Ameri Mahmoud

Mahmoud Ameri from Fremont, US has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2024-06-06

US20240181036A1

Human necessities

TRANSDERMAL ACTIVE AGENT DELIVERY DEVICES HAVING CORONAVIRUS VACCINE COATED MICRO-PROTRUSIONS

#2 | 2023-08-17

US20230255881A1

Human necessities

METHOD OF RAPIDLY ACHIEVING THERAPEUTIC CONCENTRATIONS OF TRIPTANS FOR TREATMENT OF MIGRAINES AND CLUSTER HEADACHES

#3 | 2023-07-06

US20230210762A1

Human necessities

TRANSDERMAL DRUG DELIVERY DEVICES HAVING PSILOCYBIN, LYSERGIC ACID DIETHYLAMIDE OR 3,4-METHYLENEDIOXYMETHAMPHETAMINE COATED MICROPROTRUSIONS

#4 | 2022-05-05

US20220133627A1

Human necessities

Stable Therapeutic Formulations

#5 | 2022-02-24

US20220057377A1

Physics

ANALYTICAL METHOD FOR DETERMINATION OF IN VITRO DRUG RELEASE PROFILE FROM MICRONEEDLE PATCHES

#6 | 2021-09-09

US20210275445A1

Human necessities

Method of rapidly achieving therapeutic concentrations of triptans for treatment of migraines

#7 | 2020-01-02

US20200000712A1

Human necessities

Method of rapidly achieving therapeutic concentrations of triptans for treatment of migraines and cluster headaches

#8 | 2019-03-07

US20190070103A1

Human necessities

Method of rapidly achieving therapeutic concentrations of triptans for treatment of migraines and cluster headaches

#9 | 2018-06-07

US20180153799A1

Human necessities

Method of rapidly achieving therapeutic concentrations of triptans for treatment of migraines

#10 | 2018-06-07

US20180153798A1

Human necessities

Stable Glucagon Peptide Formulations

#11 | 2017-08-24

US20170239174A1

Human necessities

Method of rapidly achieving therapeutic concentrations of triptans for treatment of migraines

#12 | 2017-05-18

US20170135951A1

Human necessities

Stable therapeutic formulations

#13 | 2016-02-25

US20160051467A1

Human necessities

Stable glucagon peptide formulations

#14 | 2015-02-26

US20150057605A1

Human necessities

Stable glucagon peptide formulations

#15 | 2014-09-18

US20140260096A1

Human necessities

Stable therapeutic formulations

#16 | 2010-09-02

US20100221305A1

Human necessities

Formulations for coated microprojections containing non-volatile counterions

#17 | 2010-06-24

US20100160895A1

Human necessities

Apparatus and method for transdermal delivery of parathyroid hormone agents

#18 | 2010-06-17

US20100152649A1

Human necessities

Apparatus for transdermal delivery of parathyroid hormone agents

#19 | 2010-05-13

US20100119568A1

Human necessities

Apparatus and method for transdermal delivery of parathyroid hormone agents

#20 | 2009-08-25

US10880702

Formulations for coated microprojections containing non-volatile counterions

#21 | 2009-05-28

US20090136554A1

Human necessities

Transdermal sustained release drug delivery

#22 | 2009-05-07

US20090117158A1

Human necessities

Transdermal sustained release drug delivery

#23 | 2008-02-14

US20080039775A1

Human necessities

Apparatus and Method for Transdermal Delivery of Parathyroid Hormone Agents to Prevent or Treat Osteopenia

#24 | 2007-08-09

US20070184096A1

Human necessities

Stable therapeutic formulations

#25 | 2006-12-07

US20060275170A1

Human necessities

Method for terminal sterilization of transdermal delivery devices

#26 | 2006-08-24

US20060188555A1

Human necessities

Therapeutic peptide formulations with improved stability

#27 | 2006-08-17

US20060182789A1

Human necessities

Apparatus and method for transdermal delivery of epoetin-based agents

#28 | 2006-08-10

US20060177494A1

Human necessities

Coated microprojections having reduced variability and method for producing same

#29 | 2006-02-23

US20060040864A1

Human necessities

Apparatus and method for transdermal delivery of vascular endothelial growth factors

#30 | 2005-12-01

US20050266011A1

Human necessities

Method and formulation for transdermal delivery of immunologically active agents

#31 | 2005-11-17

US20050256045A1

Human necessities

Apparatus and method for transdermal delivery of parathyroid hormone agents

#32 | 2005-10-13

US20050226922A1

Human necessities

Apparatus and method for transdermal delivery of fentanyl-based agents

#33 | 2005-06-09

US20050123507A1

Human necessities

Formulations for coated microprojections having controlled solubility

#34 | 2005-05-19

US20050106209A1

Human necessities

Composition and apparatus for transdermal delivery

#35 | 2005-04-28

US20050090009A1

Human necessities

Compositions of stabilized DNA for coating microprojctions

InventorID:

1080471 ⎘